Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer. - Cao J; Zhu Z; Wang H; Nichols TC; Lui GYL; Deng S; Rejto PA; VanArsdale T; Hardwick JS; Weinrich SL; Wei P (Oncogene, 2019)